Author:
Wang Duo,Feng Chan,Xiao Zeyu,Huang Cuiqing,Chen Zerong,Fang Weiming,Ma Xiaocong,Wang Xingkai,Luo Liangping,Hu Kuan,Tao Wei
Subject
Pharmaceutical Science,General Materials Science,Biomedical Engineering,Bioengineering,Biotechnology
Reference50 articles.
1. Smart nanotherapeutic targeting of tumor vasculature;Li;Acc. Chem. Res.,2019
2. Vascular disrupting agents in clinical development;Hinnen;Br. J. Cancer,2007
3. Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer;Nathan;Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res.,2012
4. A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): final survival analysis for the FACT trial;Sosa;J. Clin. Oncol.,2011
5. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling;Vincent;J. Clin. Investig.,2005
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献